Pre-made Alemtuzumab benchmark antibody ( Whole mAb, anti-CD52 therapeutic antibody, Anti-HE5/CDW52/EDDM5 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Alemtuzumab biosimilar, Whole mAb, Anti-CD52 Antibody: Anti-HE5/CDW52/EDDM5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. In CLL, it has been used as both a first line and second line treatment. In MS it is generally only recommended if other treatments have not worked. It is given by injection into a vein.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-015-1mg	1mg	3090
GMP-Bios-ab-015-10mg	10mg	Inquiry
GMP-Bios-ab-015-100mg	100mg	Inquiry
GMP-Bios-ab-015-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Alemtuzumab biosimilar, Whole mAb, Anti-CD52 Antibody: Anti-HE5/CDW52/EDDM5 therapeutic antibody
INN Name	Alemtuzumab
Target	CD52
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	1bey:HL/1ce1:HL
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2000
Year Recommended	2001
Companies	Bayer HealthCare Pharmaceuticals Inc.;Dana-Farber Cancer Institute;German CLL Study Group;Ohio State University Comprehensive Cancer Center;Sanofi;Sanofi Oncology;University of Cologne;University of Cambridge
Conditions Approved	Chronic lymphocytic leukaemia;Multiple sclerosis
Conditions Active	Lymphoma;T-cell prolymphocytic leukaemia
Conditions Discontinued	Rheumatoid arthritis;Diffuse large B cell lymphoma;Graft-versus-host disease;Sezary syndrome;T-cell lymphoma
Development Tech	na